ViiV Healthcare Ltd.

Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO® and SC through 2032 Reiterates 2024 Royalty Revenue Guidance of $520-555 million and Expectations to Generate >$1 billion in 2027 Conference Call Scheduled Today, Thursday, October 24 at 5:30am PT/8:30am ET SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update following a decision by the Opposition Division of the European Patent Office ("EPO") to revoke one of the Janssen Biotech, Inc. (Janssen) co-formulation patents for DARZALEX® (daratumumab) SC (Patent EP 3827845). "We remain confident in our strong royalty revenue projections with 8 approved partner products on the market today, which is expected to reach 10 by 2025. The EPO decision on a single co-formulation patent in Europe has no impact on our 2024 royalty revenue projections and expectations to exceed $1 billion in royalty revenues in 2027. We also project no impact on our U.S. or European royalty revenues on sales of DARZALEX FASPRO and SC through 2032. Additionally, this decision has no impact on the ability of any other Halozyme licensee to obtain co-formulation patents for their innovations," said Dr. Helen Torley, president and chief executive officer. "While we are disappointed with the EPO's decision today, if Janssen files an appeal in the case, today's decision would be suspended and the patent would remain in force until the case is finally decided," Dr. Torley concluded. Today's decision by the EPO has no impact on Halozyme's composition of matter patents in the U.S. and Europe for ENHANZE®. Halozyme will provide additional details on today's EPO decision and its intellectual property portfolio during an Investor Update conference call today, Thursday, October 24 at 5:30am PT/8:30am ET. A webcast of the live call and presentation will be available through the "Investors" section of Halozyme's corporate website at ir.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's royalty revenue projections for 2024, 2027 and through 2032). Forward-looking statements regarding the Company's business may include statements about the expected number of future approved partnered products, potential growth and receipt of royalty payments driven by our partners' development and commercialization efforts and the potential impact of the decision on a co-formulation patent referenced in this press release on the Company's 2024 royalty revenue guidance and future royalty revenues through 2032, and the ability of our licensees to obtain co-formulation patents and on certain composition of matter patents and the impact of appealing the decision. These forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues, expenditures and costs, unexpected impact of the co-formulation patent decision referenced in this press release including unexpected results or delays in our licensees' ability to obtain co-formulation patents or in appealing the decision, unexpected impacts on our composition of matter patents, unexpected results regarding the growth of the Company's business or number of future approved partnered products, or in the development, regulatory review or commercialization of the Company's partnered or proprietary products, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, the Company undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-359-3016 [email protected] Samantha Gaspar Teneo 212-886-9356 [email protected] SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024, following the close of trading. Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: . A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at . About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-359-3016 [email protected] Samantha Gaspar Teneo 212-886-9356 [email protected] SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

The treatment combines MSD’s islatravir with Gilead’s lenacapavir. Credit: Ground Picture via Shutterstock. Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II trials, following promising results from a 48-week study. The treatment combines MSD’s islatravir, an experimental nucleoside reverse transcriptase inhibitor, with Gilead’s lenacapavir, marketed as Sunlenca for use in combination with other antiretroviral drugs to treat people with multidrug-resistant HIV infection. In contrast to currently available daily HIV medications, such as Gilead’s Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg), this new option could offer a long-acting alternative for people living with HIV. In the Phase II trial (NCT05052996), 104 virologically suppressed adults on Biktarvy were randomly assigned to either continue their daily regimen or switch to the once-weekly islatravir/lenacapavir combination. At the 24-week mark, 94.2% of patients on the experimental treatment maintained viral loads below 50 copies m/L – a key threshold for HIV suppression – matching the Biktarvy group. By week 48, the new regimen continued to demonstrate non-inferior efficacy, with 94.2% of participants achieving sustained viral suppression, compared to 92.4% of those who remained on Biktarvy. These results suggest that the once-weekly combination could provide a more convenient option for patients, potentially reducing the burden of daily medication. Currently, the only long-acting HIV treatment available in the US is Viiv Healthcare’s Cabenuva, which is administered as a monthly or bi-monthly injection. This could make Gilead and MSD’s new pill an attractive alternative to those seeking a less frequent oral regimen. See Also: Editas and Genevant team up to develop gene editing therapies World Osteoporosis Day calls for urgent action to prevent fragility fractures Biktarvy is approved as a once-daily pill to treat patients living with certain types of HIV. The drug generated $11.9bn in global sales in 2023, as per Gilead’s financials. According to GlobalData’s Pharma Intelligence Center, Biktarvy will generate $15.3bn in sales in 2030. GlobalData is the parent company of Pharmaceutical Technology. In the announcement accompanying the results, Elizabeth Rhee, vice president of global clinical development of Merck Research Laboratories said: “Daily single-tablet regimens have helped to transform HIV care but can be challenging for some people to maintain. Novel HIV treatment options that allow for less frequent oral dosing have the potential to help support adherence, and address stigma faced by some individuals taking daily oral therapy.” MSD previously tried to develop a higher dose of islatravir, however it had to pause development after it led to a drop in counts of lymphocytes and CD4+ T cells in clinical trials in 2021. In MSD and Gilead’s Phase II study, there were no differences in immune cell count changes between the Biktarvy and experimental groups. Additionally, no participants discontinued because of a decrease in CD4+ T-cell or lymphocyte counts. Encouraged by these results, Gilead and MSD are now advancing the treatment in Phase III trials. Gilead is also advancing lenacapavir as a PrEP medication, a group of drugs that HIV-negative people can take to minimise the risk of contracting HIV. The company plans to use the data from two Phase III clinical trials – PURPOSE-1 (NCT04994509) and PURPOSE-2 (NCT04925752) – to support a series of global regulatory filings for lenacapavir for PrEP that will begin by the end of 2024.